Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: A preliminary report

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 8, 2012, Pages 1409-1415

  Sans, Teresa ^a   Rull, Anna ^b   Luna, Jose ^a   Mackness, Bharti ^b   Mackness, Michael ^b   Joven, Jorge ^b   Ibañez, Marcos ^a   Pariente, Rainer ^a   Rodriguez, Marta ^a   Ortin, Xavier ^a   Masdeu, Gaspar ^a   Camps, Jordi ^b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Intensive care; Monocyte chemoattractant protein 1; Paraoxonase; Sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; CREATININE; ESTERASE; GLUCONOLACTONASE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PARAOXONASE 3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ERYTHROCYTE COUNT; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; LEUKOCYTE COUNT; LINEAR REGRESSION ANALYSIS; LONGITUDINAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEPSIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AMINO ACID SEQUENCE; ARYLDIALKYLPHOSPHATASE; CHEMOKINE CCL2; FEMALE; HUMANS; INTENSIVE CARE UNITS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OXIDATIVE STRESS; PROSPECTIVE STUDIES; SEPSIS;

EID: 84867772365     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0896     Document Type: Article

References (37)

1. Marshall JC, Vincent JL, Guyatt G, Angus DC, Abraham E, Bernard G, et al. Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med 2005;33:1708-16.
2. Van Leeuwen HJ, Van Beek AP, Dallinga-Thie GM, Van Strijp JA, Verhoef J, Van Kessel KP. The role of high density lipoprotein in sepsis. Neth J Med 2001;59:102-10.
3. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 2004;21:210-21.
4. Han R. Plasma lipoproteins are important components of the immune system. Microbiol Immunol 2010;54:246-53.
5. Birjmohun RS, Van Leuven SI, Levels JH, Van't Veer C, Kuivenhoven JA, Meijers JC, et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007;27:1153-8.
6. Galley AF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 2011;107:57-64.
7. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507.
8. Rodríguez-Sanabria F, Rull A, Beltrán-Debón R, Aragonès G, Camps J, Mackness B, et al. Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. J Mol Histol 2010;41:379-86.
9. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009;46:83-106.
10. Bourquard N, Shih DM, Ng CJ, Villa-García N, Nakamura K, Stoltz DA, et al. The role of PON2 and PON3 in atherosclerosis and related traits. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The paraoxonases: their role in disease development and xenobiotic metabolism. Dordrecht: Springer, 2008:103-28.
11. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004;318:680-3.
12. Rull A, Camps J, Alonso-Villaverde C, Joven J. Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism. Mediators Inflamm 2010;2010. pii: 326580.
13. Rull A, García R, Fernández-Sender L, Beltrán- Debón R, Aragonès G, Alegret JM, et al. The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease. Curr Mol Med 2011;11:453-64.
14. Marsillach J, Camps J, Ferré N, Beltrán R, Rull A, Mackness B, et al. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol 2009;9:3.
15. Petrkova J, Sztkowska J, Hermanova Z, Lukl J, Petrek M. Monocyte chemoattractant protein-1 in patients with peripheral arterial disease. Mediators Inflamm 2004;13:39-43.
16. Marsillach J, Aragonès G, Beltrán R, Caballería J, Pedro-Botet J, Morcillo-Suárez C, et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009;42:91-8.
17. Ferré N, Marsillach J, Camps J, Mackness B, Mackness M, Riu F, et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006;45:51-9.
18. Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005;183:349-54.
19. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine, 1992. Chest 2009;136:Suppl: e28.
20. Richards G, Levy H, Laterre PF, Feldman C, Woodward B, Bates BM, et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med 2011;26:34-40.
21. Milić M, Goranović T, Holjevac JK. Correlation of APACHE II and SOFA scores with length of stay in various surgical intensive care units. Coll Antropol 2009;33:831-5.
22. Aragonès G, Guardiola M, Barreda M, Marsillach J, Beltrán-Debón R, Rull A, et al. Measurement of serum paraoxonase-3 concentration: method evaluation, reference values and influence of genotypes in a population-based study. J Lipid Res 2011;52:1055-61.
23. Gaidukov L, Tawfik D. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res 2007;48:1637-46.
24. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002;48:261-8.
25. Tanno K, Okamura T, Ohsawa M, Onoda T, Itai K, Sakata K, et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010;411:1774-80.
26. Heron M, Tejada-Vera B. Deaths: leading causes for 2005. Natl Vital Stat Rep 2009;58:1-97.
27. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313-26.
28. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007;11:R49.
29. Bossink AW, Paemen L, Jansen PM, Hack CE, Thijs LG, Van Damme J. Plasma levels of the chemokines monocyte chemotactic proteins-1 and-2 are elevated in human sepsis. Blood 1995;86:3841-7.
30. Van Leeuwen HJ, Heezius EC, Dallinga GM, Van Strijp JA, Verhoef J, Van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31:1359-66.
31. Dunham CM, Fealk MH, Sever WE. Following severe injury, hypocholesterolemia improves with convalescence but persists with organ failure or onset of infection. Crit Care 2003;7:R145-53.
32. Levels HM, Pajkrt D, Schultz M, Hoek FJ, Van Tol A, Meijers JC, et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta 2007;1771:1429-38.
33. Murch O, Collin M, Hinds CJ, Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007;33:13-24.
34. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007;33:25-35.
35. Haas MJ, Mooradian AD. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovasculardisease. Diabetes Metab Res Rev 2010;26:90-9.
36. Novak F, Vavrova L, Kodydkova J, Novak Sr F, Hynkova M, Zak A, et al. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med 2010;10:21-5.
37. Grion CM, Cardoso LT, Perazolo TF, Garcia AS, Barbosa DS, Morimoto HK, et al. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest 2010;40:330-8.